Austar Lifesciences Limited board of directors announced that the group is expected to record a substantial reduction of not less than 60% in consolidated profits attributable to the shareholders of the company for the six months ending June 30, 2015, as compared with the corresponding period in 2014, mainly attributable to: delay in recognition of revenue due to subsequent modification of users requirements for projects undertaken by the Group during the past few months; and decrease in gross profit margin for certain projects undertaken by the Group.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.84 HKD | +2.44% | +2.44% | -46.15% |
03-26 | Austar Lifesciences Limited Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
01-22 | Austar Lifesciences to Swing to Loss; Shares Drop | MT |
1st Jan change | Capi. | |
---|---|---|
-46.15% | 53.84M | |
-4.97% | 182B | |
+0.34% | 114B | |
-5.60% | 67.76B | |
+3.87% | 51.91B | |
+7.11% | 43.23B | |
+6.07% | 41.07B | |
+23.33% | 32.07B | |
+15.86% | 25B | |
-2.87% | 24.55B |
- Stock Market
- Equities
- 6118 Stock
- News Austar Lifesciences Limited
- Austar Lifesciences Limited Provides Earnings Guidance for the Six Months Ending June 30, 2015